DSIP Peptide: Why FDA Advisers Voted Against It

The FDA Pharmacy Compounding Advisory Committee, or PCAC, reviewed the DSIP peptide on July 24, 2026. FDA used the name emideltide for the substance.

The committee held two votes. One vote covered emideltide free base. The other vote covered emideltide acetate.

Both votes had the same result:

• 6 members voted yes.
• 7 members voted no.
• 1 member abstained.

The committee did not recommend either form for the 503A Bulks List.

This was an advisory vote. FDA did not ban DSIP on July 24. FDA also did not approve DSIP, Semax, or Epitalon as drugs.

What did PCAC decide?

PCAC reviewed three peptide-related substances on July 24.

Substance	Forms reviewed	Use that FDA evaluated	PCAC vote
Emideltide, or DSIP	Free base and acetate	Chronic insomnia, narcolepsy, and opioid withdrawal	6 yes, 7 no, 1 abstention
Epitalon	Free base and acetate	Insomnia	7 yes, 4 no, 1 abstention
Semax	Free base and acetate	Cerebral ischemia, migraine, and trigeminal neuralgia	8 yes, 5 no, 1 abstention

The FDA meeting page gives the official agenda and the reviewed uses. The meeting report from Fierce Pharma gives the final vote counts.

The July 24 votes followed four favorable votes on July 23. PCAC recommended BPC-157, KPV, TB-500, and MOTS-c on the first day. Read our July 23 PCAC vote report for those results.

What is DSIP peptide?

DSIP means delta sleep-inducing peptide. FDA calls it emideltide.

It is a peptide with nine amino acids. Researchers first identified it in rabbit blood. Early studies connected it to slow-wave sleep and other nervous-system effects.

The name creates a problem. Sellers and publications do not always use the same chemical description. FDA found references to free base, acetate, other salts, and related products under the DSIP name.

These forms are not automatically interchangeable. A free base and an acetate salt are different bulk drug substances. They can have different physical properties. They can also create different quality and formulation problems.

FDA reviewed both forms because the nomination records did not clearly identify one form.

For a compound overview, read the DSIP research profile. You can also review the DSIP evidence and safety page.

What is the 503A Bulks List?

Section 503A sets conditions for traditional pharmacy compounding. A compounder can use a bulk drug substance if one of these conditions applies:

1. The substance has an applicable USP or NF monograph.
2. The substance is a component of an FDA-approved drug.
3. The substance is on the 503A Bulks List.

DSIP does not meet the first two conditions. It has no applicable USP or NF drug-substance monograph. It is not a component of an FDA-approved drug.

This made the list review important. It did not turn the meeting into a drug-approval review.

The 503A process uses a balancing test. FDA and PCAC consider these questions:

• Is the substance well characterized?
• Is there a history of use in compounding?
• Is there evidence of effectiveness?
• Are there safety concerns?

The result can support or oppose list inclusion. It does not establish an approved indication, label, dose, route, or product.

Why did FDA staff oppose DSIP?

FDA's 83-page emideltide briefing document proposed that neither reviewed form should go on the list.

The agency gave four main reasons.

1. The substance identity was not clear

FDA found inconsistent naming in the nominations, certificates, public databases, and published literature.

One nomination mixed information for the free base and acetate forms. Another certificate included a molecular formula that did not match an emideltide structure. Both original nominations were later withdrawn. FDA continued the review at its own discretion.

This matters because a name alone does not prove identity. A pharmacy, laboratory, and prescriber must know which substance is present.

2. The tested route did not match the nominated route

The nominations proposed a subcutaneous product.

FDA did not identify a study that tested subcutaneous emideltide for chronic insomnia, narcolepsy, or opioid withdrawal. The available human studies mainly used intravenous administration.

A study of one route cannot prove the safety or effectiveness of another route. Absorption, formulation, exposure, and local risks can change.

This route mismatch was central to the review.

3. The human evidence was small and inconsistent

The DSIP evidence base includes old and small human studies. Some studies reported changes in sleep measures. Other studies did not reach the same result.

FDA found these common limits:

• Small sample sizes
• Weak or missing control groups
• Different treatment schedules
• Different participant groups
• Subjective outcome measures
• No useful long-term evidence
• No subcutaneous effectiveness evidence

For chronic insomnia, FDA called the evidence inconclusive and preliminary. Professional guidelines for insomnia do not discuss emideltide.

The narcolepsy evidence was smaller. FDA found one case report. A single case cannot establish effectiveness.

The opioid-withdrawal studies were open-label and uncontrolled. The studies reported some early changes, but they could not show that DSIP caused the result. Current professional guidelines do not discuss DSIP for opioid withdrawal.

4. Safety and product-quality data were incomplete

FDA found no clinical safety data for the proposed subcutaneous route.

Small intravenous studies reported headache, nausea, vertigo, and some cases of progressive hypotension after a second injection. These findings were difficult to interpret because the participants also had withdrawal symptoms.

FDA also raised product-quality questions:

• The peptide can aggregate.
• Aggregates and impurities can increase immune-response risk.
• The nominations did not provide enough impurity information.
• Endotoxin information for the proposed injectable use was incomplete.
• FDA did not find adequate nonclinical toxicity studies.
• The proposed concentration created a solubility question.

These gaps do not prove that every DSIP product causes harm. They show that the reviewed evidence could not define the risk.

Does the vote prove that DSIP does not work?

No.

The committee did not vote on a simple question such as, "Does DSIP have any biological effect?"

The committee applied the 503A balancing test. A majority decided that the available identity, quality, effectiveness, and safety evidence did not support a favorable recommendation.

Some early studies reported possible sleep effects. Those results remain part of the evidence file. The studies are too small and inconsistent to establish a reliable clinical effect.

The correct conclusion is narrow:

PCAC did not recommend emideltide free base or emideltide acetate for the 503A Bulks List on July 24, 2026.

The incorrect conclusion is:

FDA proved that DSIP can never work.

The evidence does not support that broad statement.

Why did Epitalon and Semax receive favorable votes?

FDA staff also raised evidence and quality concerns for Epitalon and Semax. PCAC still recommended both substances.

This shows that committee members can apply the balancing test differently. Some members gave more weight to use under clinician and pharmacy oversight. Other members gave more weight to missing controlled trials and uncertain product identity.

A favorable vote does not prove that Epitalon or Semax is safe or effective. It also does not make either substance an FDA-approved drug.

Read the Semax research profile and the Epitalon research profile for compound-specific evidence.

What did not change after the vote?

The vote did not do these things:

• It did not create a new federal ban on DSIP.
• It did not approve DSIP as a drug.
• It did not approve DSIP for sleep, narcolepsy, or opioid withdrawal.
• It did not validate a dose or route.
• It did not approve a product from an online vendor.
• It did not make Semax or Epitalon FDA-approved.
• It did not create an immediate final list change.

FDA states that advisory committee recommendations are non-binding. The agency will review the votes, discussion, briefing documents, and public comments.

What happens next?

FDA must make the agency decision.

The agency can agree with PCAC or reach a different conclusion. A formal list change normally requires the applicable rulemaking process. FDA can also issue policy while rulemaking continues.

There is no fixed date for the final step.

Readers must use precise terms until FDA acts:

• Accurate: PCAC recommended against the reviewed DSIP forms.
• Inaccurate: FDA issued a final DSIP ban.
• Accurate: PCAC recommended Epitalon and Semax.
• Inaccurate: FDA approved Epitalon and Semax.

For the complete meeting context, read what the FDA peptide hearing covered.

How should readers assess DSIP claims?

Start with the exact claim.

Ask these questions:

1. Does the claim identify emideltide free base, acetate, or another form?
2. Does the cited study use the same route as the claim?
3. Is the evidence from humans, animals, or cells?
4. Did the study use a control group?
5. Does the result show a clinically meaningful change?
6. Does a laboratory report identify the exact lot and substance?
7. Does the report include identity and content, not only a purity percentage?

Use our guide to verify a peptide COA before you treat a certificate as proof.

Bottom line

The July 24 result was the only negative PCAC recommendation across the seven peptide-related substances reviewed during the two-day meeting.

The DSIP vote was close. Six members supported inclusion. Seven opposed it. One abstained.

The evidence file explains the result. FDA found unclear identity, incomplete characterization, weak route-specific evidence, inconsistent human results, and missing safety data for the proposed route.

This was not a drug approval decision. It was not a final FDA list decision. It was a recommendation under the 503A compounding framework.

Sources

1. FDA: July 23-24, 2026 PCAC meeting, agenda, and materials
2. FDA: Emideltide free base and acetate briefing document
3. FDA: July 24 PCAC presentation materials
4. FDA: Introduction to the PCAC briefing documents and the 503A test
5. Fierce Pharma: Final July 24 PCAC vote report
6. PubMed: Acute and delayed effects of DSIP on human sleep
7. PubMed: DSIP in chronic insomnia
8. PubMed: DSIP in alcohol and opioid withdrawal
9. PubMed: Review of delta sleep-inducing peptide

This article is for education. It is not medical advice. It does not give dose, injection, or treatment instructions.